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ABSTRACT: Managing equine hyperinsulinemia is crucial for preventing laminitis, but our 14 
understanding of the mechanisms involved in insulin dysregulation in this species is 15 
incomplete. C-peptide is co-secreted with insulin, but is resistant to hepatic metabolism and 16 
can be used to study insulin dysregulation. This study examined C-peptide secretion in serial 17 
blood samples collected after oral and i.v. dextrose (0.75 g/kg) administration to 9 ponies 18 
(body condition score 7.1 ± 0.5). The ponies were designated as hyperinsulinemic (HI) or 19 
normoinsulinemic (NI) responders before the study, using oral glucose tests and fasted 20 
glucose-to-insulin ratios, and responses were compared between the 2 groups. C-peptide 21 
concentrations increased (P < 0.01) rapidly from fasted levels after both oral and i.v. 22 
dextrose, with similar area under the concentration-time curve (AUC) for both tests and a 23 
significant correlation with AUCinsulin. The AUCC-peptide was similar in HI and NI ponies after 24 
i.v. dextrose, indicating similar pancreatic capacity for both groups. However, for oral 25 
dextrose the AUCC-peptide and the AUCinsulin were markedly higher (P < 0.05) in the HI ponies, 26 
indicating a greater secretion rate of these peptides. Slower insulin clearance might have also 27 
contributed to the larger AUCinsulin in HI ponies, but this hypothesis requires further 28 
investigation with specific measures of hepatic insulin clearance.  29 
Key words: C-peptide, equine, horse, hyperinsulinemia, insulin, laminitis  30 
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INTRODUCTION 31 
Insulin dysregulation is increasingly recognized in horses and ponies and is usually 32 
coincident with increased fat mass, insulin resistance (IR) and/or amplified insulin responses to 33 
ingested carbohydrate (Frank and Tadros, 2014). Laminitis, the painful disengagement of vital 34 
soft-tissue structures located between the pedal bone and hoof wall, can be initiated by 35 
hyperinsulinemia (Asplin et al., 2007; de Laat et al., 2010). Often diagnosed in association with 36 
laminitis, insulin dysregulation is now also frequently detected before the onset of lamellar 37 
dysfunction and this represents an opportunity to prevent laminitis. Development of new 38 
treatment options for insulin dysregulation is limited by incomplete understanding of the 39 
mechanisms involved in equine hyperinsulinemia.  40 
Proinsulin, comprising conjoined insulin and C-peptide, undergoes sequential, enzymatic 41 
cleavage to produce insulin and C-peptide in proportionate amounts (Steiner, 2011). Studies in 42 
other species have shown that after secretion, insulin is substantially extracted during its first-43 
passage through the liver, before reaching the systemic circulation. In contrast, the hepatic 44 
clearance of C-peptide is negligible and its half-life is ~6 times longer than that of insulin, so 45 
circulating concentrations are usually several-fold higher (Marques et al., 2004). Thus, in 46 
humans, C-peptide concentrations are used to approximate insulin secretion and pancreatic β-cell 47 
activity (Fujita et al., 2015). Further, examination of C-peptide and insulin ratios can provide an 48 
indication of hepatic insulin clearance (Meier et al., 2005). C-peptide has also recently been 49 
reported to have receptor binding capability and independent biological functions pertinent to 50 
laminitis pathophysiology, such as stimulation of blood flow and insulinomimetic actions 51 
(Marques et al., 2004; Wang et al., 2012; McKillop et al., 2014; Yosten et al., 2014).  52 
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Given current research and clinical interest in equine insulin dysregulation, it is 53 
surprising that C-peptide has only been examined in a small number of studies (Geor et al., 2010; 54 
Toth et al., 2010). Clearly, further investigation of C-peptide may be rewarding for equine 55 
metabolic disease. Thus, this study aimed to compare C-peptide and insulin responses to oral and 56 
i.v. glucose in ponies with and without insulin dysregulation, to test 2 hypotheses: firstly, that 57 
hyperinsulinemia results from increased insulin production rather than decreased insulin 58 
clearance; secondly, that hyperinsulinemia associated with the oral consumption of 59 
carbohydrates is not necessarily associated with peripheral IR (i.e. that it may occur in ponies 60 
that show no impairment in their response to i.v. dextrose).  61 
MATERIALS AND METHODS 62 
Sample population  63 
Nine, university-owned, mixed-breed ponies (Table 1) were stratified for insulin 64 
responsiveness using both basal and dynamic tests one week before the study. This was done 65 
using fasted glucose-to-insulin ratios (FGIR) and a standard oral glucose test (OGT, 1 g/kg 66 
dextrose in a low glycemic ration; serum collected at 0 h and 2 h); (Frank and Tadros, 2014). 67 
Ponies with an FGIR below 4.5, and a serum insulin concentration of > 520 pM 2 h after oral 68 
dextrose, were classified as hyperinsulinemic (HI). An FGIR above 10, and a serum insulin 69 
concentration < 222 pM 2 h post dextrose, was designated as normoinsulinemic (NI). The ponies 70 
were all overweight (body condition score 7.1 ± 0.5), with the HI group having evidence of 71 
regional adiposity (Henneke et al., 1983; Carter et al., 2009). 72 
Hepatic and renal function were assessed in all ponies with routine biochemistry testing 73 
for glutamate dehydrogenase, gamma glutamyl transferase, albumin:globulin (hepatic function) 74 
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and urea, creatinine (renal function). The ponies remained healthy: hepatic and renal function 75 
parameters within the accepted reference ranges for the assays used, and free from laminitis. 76 
Water intake was unrestricted. Ethical approval for the study was granted by the University 77 
Animal Ethics Care and Use Committee (SVS/QUT/109/13). 78 
Study design 79 
Initially, dextrose (0.75 g/kg; lower dose than OGT selected for palatability reasons) was 80 
administered orally to ponies as a component of an otherwise low glycemic ration. Seven days 81 
later, dextrose (0.75 g/kg) was administered i.v. via an indwelling catheter (Mila, Erlanger, KY) 82 
placed aseptically in the left jugular vein. The rate of glucose infusion was individualized for 83 
each pony, to match their rate of feed intake which was measured during the oral test (the 84 
average infusion time was 52.2 ± 3.1 min). The ponies were fed the same low glycemic base 85 
ration for both tests to ensure that the total energy intake was equivalent in the two parts of the 86 
study; 200 g bran (12.6 MJ/kg DM ME, 16.6% CP, 16% starch), 500 mL tap water, 0.3% BW 87 
lucerne chaff (10.9 MJ/kg DM ME, 24.4% CP, <2% starch, WSC 8%). No feed refusals, or 88 
adverse reactions to the oral or i.v. dextrose doses, were observed. Tests were performed at 0800 89 
h after an overnight fast. Blood samples (6 mL) were collected before (0 h) and after dosing at 90 
30, 60, 90, 120, 180 and 360 min, with additional sampling at 15 and 45 min for the i.v. test. 91 
Blood glucose was analysed immediately using whole blood with a handheld glucometer 92 
validated for use in horses by the investigators (de Laat et al., 2012). The remaining blood was 93 
placed into plain tubes, allowed to clot and then centrifuged (10 min, 1500 x g) to facilitate 94 
serum separation. The serum was dispensed into multiple aliquots before freezing and storage at 95 
-80˚C to avoid repeated freeze/thaw cycles. 96 
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Assays  97 
Serum insulin concentrations were measured with an equine-specific ELISA (Mercodia, 98 
Uppsala, Sweden) validated in-house (intra-assay CV 5.9%; inter-assay CV 7% (low-range) and 99 
6.6% (high-range)). In the absence of a suitable assay for C-peptide, 7 commercially available 100 
ELISAs were evaluated to determine their suitability for use with equine samples. Multi-101 
donation pooled samples expected to contain ‘low’, ‘mid’ and ‘high’ C-peptide concentrations 102 
were prepared using archived equine serum samples with known insulin concentrations. The 103 
expected C-peptide concentration was predicted based on the premise that the secretion of C-104 
peptide occurs in a 1:1 ratio with insulin. In addition to the pooled samples, OGT samples (0 and 105 
2 h) from the 9 ponies above were included with each assay to provide further information.  106 
The assays were assessed for cross-reactivity with equine serum, precision and accuracy. 107 
The specificity of these assays for measuring equine C-peptide, and its cross-reactivity with 108 
equine insulin cannot be determined precisely, until these peptides are available in pure form for 109 
use as assay standards. The same samples, assayed in duplicate, were used to validate all 110 
ELISAs, and the standards were assayed in triplicate. Cross-reactivity between equine C-peptide 111 
and the antibody supplied with each kit was determined by the level of antibody binding that 112 
occurred in the presence of equine serum. Precision was assessed by the intra-assay CV for 6 113 
replicates of the high, mid and low-range pooled samples. Where an assay was deemed 114 
acceptable (CV < 10%), inter-assay CV was also calculated. Recovery after the addition of an 115 
assay standard was assessed for each pooled sample, and was used as an indicator of potential 116 
assay interference, for example from binding proteins. Pooled samples were incubated overnight 117 
with a mid-range standard (1:1) to allow equilibration before analysis. Recovery on dilution of 118 
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pooled samples with assay buffer (1:1, 3:4, 1:2 and 1:4) was used to assess assay accuracy, with 119 
results assessed for linearity (r2). 120 
Statistical analyses 121 
Serial time-points were compared with repeated measures ANOVA using a general linear 122 
model with post-hoc analysis (Holm-Sidak method). Comparison of AUC (area under the curve 123 
determined by the trapezoidal method) results for the i.v. and oral tests was made with a paired t-124 
test. Comparisons between HI and NI groups used an unpaired t-test. Correlation co-efficients 125 
were estimated using Pearson’s test, and linearity was determined by simple linear regression. 126 
The fraction of the insulin cleared from the systemic circulation was estimated using the equation  127 
ሾ஼ି௣௘௣௧௜ௗ௘ሿ	ି	ሾூ௡௦௨௟௜௡ሿ
ሾ஼ି௣௘௣௧௜ௗ௘ሿ  and calculated as the percent difference. This estimate of clearance relies on 128 
the assumptions that C-peptide and insulin are co-secreted in equimolar amounts and that the 129 
clearance of C-peptide is negligible (Rubenstein et al., 1972). Data were analysed with 130 
SigmaPlot v. 12.5 (Systat software Inc, San Jose, CA) and are reported as mean ± SEM. 131 
Significance was set at P < 0.05.	132 
RESULTS 133 
C-peptide assay evaluation 134 
Results of the ELISA kits that demonstrated sufficient cross-reactivity are reported in 135 
Table 2. Four of the 7 assays evaluated failed to demonstrate sufficient cross-reactivity with 136 
equine C-peptide (Alpha diagnostic #0040, Alpco 80-CPTRT-E01, Millipore EZHCP-20K, 137 
Mercodia 10-1136-01). Of the remaining 3 assays 1 returned unacceptable results for linearity, 138 
recovery and precision. The only “equine-specific” kit tested (immunogen of the detection 139 
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antibody is a synthetic peptide corresponding to equine C-peptide aa57-87 conjugated to bovine 140 
thyroglobulin) did show cross-reactivity, but also performed at a sub-optimal level with poor 141 
precision and variable recovery values. The remaining ELISA (Abcam, Cambridge, UK) 142 
demonstrated cross-reactivity and good linearity, but needed to be improved, particularly for the 143 
samples likely to contain low concentrations of C-peptide. This assay was selected for further 144 
optimization and was re-evaluated using pre-processed samples.  145 
To remove large proteins and contaminants, serum samples (200 µL) were passed 146 
through a low-protein-binding, cellulose acetate filter (0.22 µm, Co-star Spin-X, Corning Inc, NY, 147 
USA) by centrifugation for 45 s (12,700 x g). This simple and rapid processing step improved the 148 
assay precision and accuracy for high and mid-range samples, but not for low-range pooled 149 
samples that fell below the lowest standard. The inter-assay CV was 10.1%. The linearity of 150 
diluted mid and high-range samples was excellent. However, the linearity of the low-range 151 
samples after processing could not be determined given that these samples were below the lowest 152 
standard. As such, we suggest that the safe limit of detection for C-peptide in horse serum when 153 
using this test is ~57 pM. Expected results (based on serum insulin concentration) were 154 
consistent with observed results for the 18 filtered OGT screening samples during validation of 155 
this assay (data not shown) and results were consistent with the anticipated behaviour of C-156 
peptide in a biological system. Given that the kit standards were of human origin for C-peptide 157 
and porcine origin for insulin, it is important to stress that the reported concentrations of insulin 158 
and C-peptide actually represent human and porcine equivalents of the immunoreactive peptides.  159 
Intravenous vs. oral glucose 160 
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C-peptide concentrations increased (P < 0.01) rapidly from basal, fasted levels to peak 2-161 
3 h after oral and i.v. dextrose administration (Fig. 1). Overall, C-peptide concentrations during 162 
the 6 h sampling period were similar with both tests, with no difference in AUC (oral: 4745 ± 163 
1250, i.v.: 5210 ± 1089 pM.h/L). C-peptide concentrations were not significantly different from 164 
baseline levels 6 h after either the i.v. (296 pM), or oral (652 pM; P = 0.067), test (Fig. 1). As 165 
expected, the pattern of insulin secretion in response to oral and i.v. dextrose mirrored that of C-166 
peptide (Fig. 1), with C-peptide concentrations remaining higher than insulin throughout both 167 
tests (mean insulin-to-C-peptide ratio < 1 at all time-points).  168 
The insulin AUC was lower (P < 0.01) for the oral test (1999 ± 449 pM.h/L), compared 169 
to i.v. (3072 ± 278 pM.h/L), which may suggest differences in insulin clearance during tests, 170 
given that AUCC-peptide did not differ between tests. The fractional difference in insulin and C-171 
peptide concentrations indicated that the clearance of insulin was greater (P < 0.05) 90 min after 172 
dosing for the oral test, compared to the i.v. test (62% vs. 28%, respectively), which likely 173 
reflects the time taken for absorption (Fig. 1). Lastly, the AUCC-peptide showed a positive 174 
correlation with AUCinsulin, for both the oral and i.v. test (Fig. 2).  175 
Differences due to insulin responsiveness 176 
The secretion of C-peptide after oral dextrose was significantly lower in NI ponies, than 177 
HI ponies (Fig. 3A). However, the C-peptide response to i.v. dextrose administration was similar 178 
in both HI and NI ponies (Fig. 3B). In addition, the C-peptide concentration remained elevated 179 
(P < 0.05) in the HI group 6 h after oral dextrose consumption. The AUC was larger (P < 0.05) 180 
for C-peptide, insulin and glucose in HI ponies, compared with NI ponies, for the oral test, but 181 
not different between groups for the i.v test (Fig. 4). Within groups, the AUC for C-peptide, 182 
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insulin and glucose was lower (P < 0.05) after oral dextrose consumption than after i.v. dextrose 183 
in NI ponies, while the opposite was observed (P = 0.05) for the HI group for AUCC-peptide (Fig. 184 
4).  185 
Using C-peptide to calculate the fractional clearance of insulin can be instructive in 186 
determining the extent of insulin metabolism. However, statistical analyses of clearance data to 187 
compare groups were not undertaken, due to the variability in these data (related to small sample 188 
size). Visual inspection of these data may indicate that decreased clearance of insulin occurs in 189 
HI ponies e.g. the fraction of insulin cleared 60 min after dextrose administration was ~60% in 190 
NI ponies for both tests, and only 30% and 10% in HI ponies for the for the oral and i.v. tests, 191 
respectively. The mean insulin-to-C-peptide ratio for basal, fasted samples was consistent across 192 
tests and did not differ between HI and NI groups (HI; 0.72 ± 0.13, NI; 0.71 ± 0.16).  193 
DISCUSSION 194 
This study has demonstrated that C-peptide concentrations increase markedly after oral 195 
carbohydrate ingestion in some ponies, consistent with the hypothesis that hyperinsulinemia 196 
occurs in these ponies as a result of increased insulin secretion, and not solely a decrease in 197 
insulin clearance. We have also shown that insulin secretory responses to oral carbohydrates can 198 
differ in ponies that have similar responses to i.v. dextrose, consistent with the hypothesis that 199 
peripheral IR is not required for hyperinsulinemia.  200 
To our knowledge, this is the first report of the C-peptide response to oral dextrose in 201 
horses or ponies. Our data clearly indicate that C-peptide secretion increases at a similar rate 202 
after both i.v. and oral dextrose in ponies, and this is consistent with findings in other species 203 
(Hampton et al., 1986; Montgomery et al., 1996; Frangioudakis et al., 2008). An increase in C-204 
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peptide release after an i.v. glucose bolus (at a lower dose rate of 300 mg/kg) has also been 205 
reported previously in horses (Toth et al., 2010), with C-peptide concentrations remaining 206 
elevated for only 100 min post-bolus, compared to 180 min in the current study. Notably, the 207 
secretion of C-peptide was 7-fold higher in HI ponies after oral dextrose consumption, compared 208 
to NI ponies. This finding is consistent with the greater insulin release that has been reported 209 
after carbohydrate-rich meal consumption in horses previously classified as insulin 210 
dysregulated/resistant, compared to healthy animals (Bamford et al., 2014). Given that there was 211 
no apparent difference in the response to i.v. dextrose between groups in the current study, use of 212 
the terms insulin-resistant and insulin-sensitive would have been misleading in the present 213 
context.  214 
Despite a similar C-peptide and insulin response to i.v. dextrose in both groups of ponies, 215 
the NI ponies responded to the slower absorption of oral dextrose as expected, with less marked 216 
insulin and C-peptide release. However, the HI ponies responded with greater magnitude to oral 217 
dextrose, than to i.v. delivery, suggesting that orally absorbed glucose may have initiated an 218 
additional pancreatic stimulus, such as the release of incretin hormones, in this group. Incretin 219 
hormones, such as glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, are 220 
secreted in response to an oral carbohydrate load, and in addition to glucose, stimulate insulin 221 
secretion in several species (Dupre, 2005; Baggio and Drucker, 2007; Yoder et al., 2010). 222 
Evidence of a functional enteroinsular axis has been shown in horses/ponies previously 223 
(Dühlmeier et al., 2001; Bamford et al., 2015), and we have recently shown that post-prandial 224 
incretin release varies with metabolic function in ponies (de Laat et al., 2015). The marked 225 
insulin secretion by the pancreas after oral carbohydrate in HI ponies places them at significant 226 
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risk of laminitis, and studies to further elucidate the casual mechanism behind this 227 
disproportionate response are urgently needed. 228 
The finding that C-peptide and insulin secretion was enhanced in HI ponies also 229 
highlights the important question of the mechanism of hyperinsulinemia in the horse. In theory, 230 
increases in circulating insulin could result from either increased production or reduced 231 
clearance. Although we cannot eliminate an alteration in clearance as a contributing factor, our 232 
results point to increased production as a major factor. This increased insulin production could 233 
result from either the actions of insulin secretagogues, as discussed above, or differences in 234 
glucose dynamics. These include less glucose uptake by peripheral tissues leading to a prolonged 235 
glucose stimulus, more glucose absorption from the gut, or less hepatic clearance of glucose in 236 
HI ponies. While further investigations are required to examine the relative contribution of 237 
independent pancreatic stimuli, such as glucose and/or incretin hormones, or feedback 238 
mechanisms on insulin secretion, we have recently demonstrated that ponies can be hyper-239 
responsive to oral carbohydrate without changes in peripheral glucose uptake or clearance (de 240 
Laat et al., 2015). Nevertheless, our results are consistent with the theory that hyper-241 
responsiveness to oral carbohydrates is a driver of hyperinsulinemia in the horse, which may or 242 
may not result in tissue IR (de Laat et al., 2015). Furthermore, our present results do not indicate 243 
any difference in peripheral insulin responsiveness between the small groups of HI and NI ponies 244 
examined here, despite marked differences in their oral response. 245 
The finding that C-peptide concentrations were consistently higher than insulin after i.v. 246 
and oral dextrose was expected, and is most likely a reflection of the fact that C-Peptide 247 
undergoes minimal hepatic metabolism, which is not the case for insulin (Polonsky et al., 1986). 248 
First-pass hepatic metabolism and excretion rates for insulin have been reported as 50% in the 249 
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dog and up to 80% in humans (Meier et al., 2005). Data from the current study suggests that 250 
insulin clearance rates are around 30% in the basal, fasted state, increasing to a peak of ~60% 251 
after dextrose administration. However, these estimates are based on low sample numbers, as 252 
well as the assumption that the heterologous assay systems used accurately reflect the relative 253 
amounts of C-peptide and insulin in the circulation. Studies that sample directly from the portal 254 
vein and assays using equine standards are required to measure hepatic clearance accurately. 255 
Thus, the subject of hepatic insulin clearance and its contribution to equine hyperinsulinemia is 256 
less well defined at this point.  257 
In summary, our results support the hypothesis that the hyperinsulinemia observed when 258 
certain ponies ingest large quantities of non-structural carbohydrates is the result of increased 259 
insulin secretion, with possible changes in insulin metabolism playing a secondary role. Further, 260 
this increase in secretion is not necessarily associated with peripheral tissue IR, but is likely the 261 
result of either incretin action and/or alterations in glucose dynamics. The implication of our 262 
findings is that future research and diagnostic methods should focus on hepatic and 263 
gastrointestinal function as primary factors in insulin dysregulation to unlock the cause of this 264 
condition and provide new therapeutic approaches to the prevention of laminitis. 265 
  266 
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Table 1: Sample population characteristics 345 
Group n Sex Age (years) BCS (/9) CNS (/5) FGIR 2 h Insulin (pM)
NI 4 1 F; 3 M 11.8 ± 2 6.5 ± 1 1.3 ± 0.8a 15 ± 2.1b 136 ± 16c 
HI 5 3 F; 2 M 13 ± 3.3 7.4 ± 0.5 2.8 ± 0.4 2.6 ± 0.4 764 ± 111 
aP = 0.04, bP = 0.0002, cP = 0.01 346 
 347 
  348 
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Table 2: Evaluation of ELISAs assessed for measurement of equine C-peptide.  349 
Repeat evaluation of the Abcam assay with filtered samples is indicated in brackets. 350 
Assay Capture 
Antibody 
Standards Intra-
assay CV 
(%) 
Recovery on 
addition (%) 
Linearity 
(r2) 
LOD1 
(pM) 
2Abcam 
Low 
Mid 
High 
Human 
monoclonal 
Recombinant 
human 
 
23.8 (-) 
10.4 (10.5) 
10.6 (7.7) 
 
49.0 (79.0) 
68.6 (98.9) 
91.0 (92.1) 
 
- 
0.90 (0.98) 
0.99 (0.99) 
3.31 
(57.0) 
3Biosource 
Low  
Mid  
High 
Mouse 
monoclonal  
Recombinant 
(unknown) 
 
10.3 
20.1 
37.3 
 
128 
82.3 
71.3 
 
 
0.86 
0.63 
33.1 
4USCN 
Low 
Mid 
High 
Human 
monoclonal 
Recombinant 
human 
 
67.9 
55.3 
33.1 
 
320 
295 
284 
 
 
-0.46 
0.91 
4.3 
1Limit of detection for each kit as indicated by the manufacturer, not the actual limit of detection for equine C-peptide; 351 
2Abcam, Cambridge, UK, ab178641; 3Biosource, San Diego, CA, MBS019653; 4USCN, Houston, TX, CEA447Hu 352 
  353 
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FIGURES 354 
 355 
Fig. 1. Serum C-peptide concentrations (●) were similar in response to oral (A) and i.v. (B) dextrose 356 
administration (0.75 g/kg) to 9 ponies. Insulin (○) concentrations in response to both oral, and i.v., 357 
dextrose showed a similar pattern, but at reduced concentrations compared with C-peptide (●). *P < 0.05 358 
compared with 0 h time-point. 359 
 360 
 361 
Fig. 2. C-peptide and insulin responses to oral and intravenous dextrose are positively correlated. A: The 362 
AUC for C-peptide over a 6 h sampling period after oral administration of dextrose (0.75 g/kg) in 9 363 
ponies was strongly correlated with AUC for insulin (slope = 0.322, y intercept = 470). B: The AUC for 364 
C-Peptide over a 6 h sampling period after i.v. dextrose administration (0.75 g/kg) was also correlated 365 
with the AUC for insulin (slope = 0.171, y intercept = 2181). 366 
19 
 
 367 
Fig. 3. A: Despite similar basal, fasted C-peptide concentrations, oral dextrose results in a larger C-368 
peptide response in HI ponies (●) than NI ponies (▼), with C-peptide concentration remaining elevated at 369 
6 h post-dosing. B: The secretion of C-peptide (closed symbols) and insulin (open symbols) after i.v. 370 
dextrose is similar between hyperinsulinemic (HI; circles) and normoinsulinemic (NI; triangles) ponies. A 371 
similar pattern, but of lower magnitude, is seen for serum insulin secretion in the two groups (open 372 
symbols).  373 
 374 
 375 
Fig. 4. The area under the concentration-time curve (AUC) is greater (a) after oral dextrose (0.75 g/kg 376 
BW) for C-peptide (A; P = 0.01), insulin (B; P = 0.01) and glucose (C; P = 0.02) in hyperinsulinemic 377 
(HI) ponies, compared to normoinsulinemic (NI) ponies. There was no difference between groups after 378 
i.v. dextrose administration for any metabolite. Within groups, NI ponies secrete less (b) C-peptide (A; P 379 
= 0.03), insulin (B; P = 0.02) and glucose (C; P = 0.003) after oral dextrose, compared with i.v. 380 
administration.  381 
